# Studies of a new checkpoint regulator in the control of intestinal inflammation

> **NIH NIH R01** · METHODIST HOSPITAL RESEARCH INSTITUTE · 2021 · $403,750

## Abstract

Project Summary
The innate immune system is the first line of host defense against invading pathogenic microorganisms. Innate
immune cells can recognize these pathogens to induce cytokines against infections. However, this immune
response must be tightly regulated to effectively eliminate invading microorganisms while minimizing tissue
inflammation. Protein ubiquitination is important both in signal transduction and in proteasome-mediated protein
degradation and is a pivotal regulatory mechanism for the innate immune system. A key component of the
ubiquitination system is E3 ligase to specifically recognize the substrate for modification. We recently found that
a TRIM family member, E3 ligase TRIM29, is highly expressed in intestinal epithelial cells (IECs). IECs act as a
physical barrier between the external environment and the mucosal immune system. Importantly, after activation,
IECs become innate immune-like cells to produce robust proinflammatory cytokines. We posit that TRIM29 is a
key immune regulator to suppress innate immune response in a cell/tissue-specific manner to reduce intestinal
inflammation. Notably, in the gut, genes encoding inflammasome components such as CARD9, NLRP3 and
Caspases are associated with intestinal inflammation, and mice deficient in these genes are susceptible to colitis
and fungal infection. However, hyperactive inflammasome signaling and uncontrolled IL-1 family cytokines lead
to immune disorders and inflammatory disease. For instance, overproduction of inflammasome cytokine IL-18,
excessive activation of NLRP3-inflammasome, or aberrant immune response to fungus play a major pathogenic
role in colitis. Thus, this immune response must be finely tuned during immune activation for optimal protection
against infections while avoiding unwanted inflammation. However, little is known about how such activation is
terminated. Our preliminary studies show that TRIM29 negatively regulates IL-1 family cytokines produced by
IECs during colitis or fungal infection. Moreover, expression of TRIM29 itself is significantly downregulated in
inflamed colons, whereas production of IL-1 family cytokines is elevated. However, it is unknown whether lost
expression of TRIM29 is regulated by IL-1 family cytokines and/or epigenetic modifications to control responses
to environment stimuli in the intestines. We hypothesize that TRIM29 expression in IECs is a checkpoint
regulator of IL-1 family cytokines crucial to reduce intestinal inflammation in colitis and fungal infection.
We propose the following three aims to test this hypothesis: (1) To dissect molecular pathways that control
TRIM29 expression in epithelial cells under normal and inflammatory conditions; (2) To define the mechanism
by which TRIM29 inhibits IL-1 inflammation; (3) To investigate in vivo functions of TRIM29 in regulating IECs
function in colitis and anti-fungal immunity.

## Key facts

- **NIH application ID:** 10271880
- **Project number:** 1R01AI155488-01A1
- **Recipient organization:** METHODIST HOSPITAL RESEARCH INSTITUTE
- **Principal Investigator:** Zhiqiang Zhang
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $403,750
- **Award type:** 1
- **Project period:** 2021-06-07 → 2026-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10271880

## Citation

> US National Institutes of Health, RePORTER application 10271880, Studies of a new checkpoint regulator in the control of intestinal inflammation (1R01AI155488-01A1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10271880. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*